Publication date: Aug 01, 2024
Endothelial dysfunction represents a measurable and early manifestation of vascular disease. Emerging evidence suggests cardiovascular risk remains elevated after COVID-19 infection for at least 12 months, regardless of cardiovascular disease status prior to infection. We review the relationship between the severity of endothelial dysfunction and the severity of acute COVID-19 illness, the degree of impairment following recovery in both those with and without postacute sequalae SARS-CoV-2 infection, and current therapeutic efforts targeting endothelial function in patients following COVID-19 infection. We identify gaps in the literature to highlight specific areas where clinical research efforts hold promise for progress in understanding the connections between endothelial function, COVID-19, and clinical outcomes that will lead to beneficial therapeutics.
Concepts | Keywords |
---|---|
12months | COVID-19 |
Cardiovascular | endothelial dysfunction |
Covid | myocardial infarction |
Endothelial | PASC |
Postacute | SARS-CoV-2 |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | COVID-19 |
disease | MESH | vascular disease |
disease | MESH | infection |
disease | MESH | cardiovascular disease |
pathway | REACTOME | SARS-CoV-2 Infection |
disease | MESH | Long Covid |
disease | MESH | myocardial infarction |